» Articles » PMID: 35361809

Predicting Non-response to Multimodal Day Clinic Treatment in Severely Impaired Depressed Patients: a Machine Learning Approach

Overview
Journal Sci Rep
Specialty Science
Date 2022 Apr 1
PMID 35361809
Authors
Affiliations
Soon will be listed here.
Abstract

A considerable number of depressed patients do not respond to treatment. Accurate prediction of non-response to routine clinical care may help in treatment planning and improve results. A longitudinal sample of N = 239 depressed patients was assessed at admission to multi-modal day clinic treatment, after six weeks, and at discharge. First, patient's treatment response was modelled by identifying longitudinal trajectories using the Hamilton Depression Rating Scale (HDRS-17). Then, individual items of the HDRS-17 at admission as well as individual patient characteristics were entered as predictors of response/non-response trajectories into the binary classification model (eXtremeGradient Boosting; XGBoost). The model was evaluated on a hold-out set and explained in human-interpretable form by SHapley Additive explanation (SHAP) values. The prediction model yielded a multi-class AUC = 0.80 in the hold-out set. The predictive power for the binary classification yielded an AUC = 0.83 (sensitivity = .80, specificity = .77). Most relevant predictors for non-response were insomnia symptoms, younger age, anxiety symptoms, depressed mood, being unemployed, suicidal ideation and somatic symptoms of depressive disorder. Non-responders to routine treatment for depression can be identified and screened for potential next-generation treatments. Such predictors may help personalize treatment and improve treatment response.

Citing Articles

The application of artificial intelligence in insomnia, anxiety, and depression: A bibliometric analysis.

Lu E, Zhang D, Han M, Wang S, He L Digit Health. 2025; 11:20552076251324456.

PMID: 40035038 PMC: 11873874. DOI: 10.1177/20552076251324456.


Effects of an Artificial Intelligence Platform for Behavioral Interventions on Depression and Anxiety Symptoms: Randomized Clinical Trial.

Sadeh-Sharvit S, Camp T, Horton S, Hefner J, Berry J, Grossman E J Med Internet Res. 2023; 25:e46781.

PMID: 37428547 PMC: 10366966. DOI: 10.2196/46781.

References
1.
Kessler R, Chiu W, Demler O, Merikangas K, Walters E . Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005; 62(6):617-27. PMC: 2847357. DOI: 10.1001/archpsyc.62.6.617. View

2.
Zimmerman M, Clark H, Multach M, Walsh E, Rosenstein L, Gazarian D . Have Treatment Studies of Depression Become Even Less Generalizable? A Review of the Inclusion and Exclusion Criteria Used in Placebo-Controlled Antidepressant Efficacy Trials Published During the Past 20 Years. Mayo Clin Proc. 2015; 90(9):1180-6. DOI: 10.1016/j.mayocp.2015.06.016. View

3.
Kessler R, van Loo H, Wardenaar K, Bossarte R, Brenner L, Cai T . Testing a machine-learning algorithm to predict the persistence and severity of major depressive disorder from baseline self-reports. Mol Psychiatry. 2016; 21(10):1366-71. PMC: 4935654. DOI: 10.1038/mp.2015.198. View

4.
Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez J . pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics. 2011; 12:77. PMC: 3068975. DOI: 10.1186/1471-2105-12-77. View

5.
Lorant V, Croux C, Weich S, Deliege D, Mackenbach J, Ansseau M . Depression and socio-economic risk factors: 7-year longitudinal population study. Br J Psychiatry. 2007; 190:293-8. DOI: 10.1192/bjp.bp.105.020040. View